



European Medicines Agency

Doc. Ref. EMEA/757733/2009
P/240/2009

EUROPEAN MEDICINES AGENCY DECISION

of 1 December 2009

on the granting of a product specific waiver for saxagliptin / metformin (EMA-000644-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

EUROPEAN MEDICINES AGENCY DECISION

of 1 December 2009

on the granting of a product specific waiver for saxagliptin / metformin (EMEA-000644-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

THE EUROPEAN MEDICINES AGENCY,

Having regard to the Treaty establishing the European Community,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use as amended and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Bristol-Myers Squibb / AstraZeneca EEIG on 10 July 2009 under Article 13 of Regulation (EC) No 1901/2006 as amended,

Having regard to the Opinion of the Paediatric Committee of the European Medicines Agency, issued on 16 October 2009 in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended,

Having regard to Article 25 of Regulation (EC) No 1901/2006 as amended,

WHEREAS:

- (1) The Paediatric Committee has given an opinion on the granting of a product specific waiver,
- (2) It is therefore appropriate to adopt a Decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1

² OJ L 136, 30.4.2004, p. 1

HAS ADOPTED THIS DECISION:

Article 1

A waiver for saxagliptin / metformin, film-coated tablets, oral use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted,

Article 2

This decision is addressed to Bristol-Myers Squibb / AstraZeneca EEIG, Bristol-Myers Squibb House, Uxbridge Business Park, Sanderson Road, Uxbridge, UB8 1DH, United Kingdom.

Done at London, 1 December 2009

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)



European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use

Doc. Ref. EMEA/PDCO/650539/2009
EMEA-000644-PIP01-09

OPINION OF THE PAEDIATRIC COMMITTEE ON THE GRANTING OF A PRODUCT-SPECIFIC WAIVER

Scope of the application

Active substance(s):
Saxagliptin / metformin

Condition(s):
Type 2 diabetes

Pharmaceutical form(s):
Film-coated tablets

Route(s) of administration:
Oral use

Name/corporate name of the waiver applicant:
Bristol-Myers Squibb / AstraZeneca EEIG

Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Bristol-Myers Squibb / AstraZeneca EEIG submitted to the EMA on 10 July 2009 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 20 August 2009.

Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report, to grant a product-specific waiver for all subsets of the paediatric population for the above mentioned condition in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Icelandic and the Norwegian Paediatric Committee members do agree with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the Agency, together with its appendix.

London, 16 October 2009

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

ANNEX I
GROUND FOR THE GRANTING OF THE WAIVER

GROUNDNS FOR THE GRANTING OF THE WAIVER

- **Condition**

Type 2 Diabetes

The waiver applies to:

All subsets of the paediatric population from birth to less than 18 years of age for film-coated tablets for oral use on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.